Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Greenbaum

Showing results (201-210 of 225) with videos related to

Pageof 23
Sort By:
Diabetes Care|February 2, 2023
CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention StudyDarrell M Wilson, Susan L Pietropaolo, Maria Acevedo-Calado, et al.
Diabetes Care|July 18, 2018
Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA<sub>1c</sub> in New-Onset Type 1 DiabetesMichael J Haller, Desmond A Schatz, Jay S Skyler, et al.
Pancreas|October 7, 2022
Assessing the Pathophysiology of Hyperglycemia in the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis ConsortiumKathleen M Dungan, Phil A Hart, Dana K Andersen, et al.
Diabetes Care|December 12, 2018
Proinsulin Secretion Is a Persistent Feature of Type 1 DiabetesEmily K Sims, Henry T Bahnson, Julius Nyalwidhe, et al.
The New England Journal of Medicine|June 11, 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 DiabetesKevan C Herold, Brian N Bundy, S Alice Long, et al.
Diabetes Care|April 24, 2019
Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care 2019;42:258-264Emily K Sims, Henry T Bahnson, Julius Nyalwidhe, et al.
Pancreas|October 7, 2022
Recruitment and Retention Strategies for the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis ConsortiumCemal Yazici, Anne-Marie Dyer, Darwin L Conwell, et al.
Diabetes|April 11, 2019
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA<sub>1c</sub>, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial DataMichael J Haller, S Alice Long, J Lori Blanchfield, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
Diabetes Care|March 15, 2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled TrialWilliam E Russell, Brian N Bundy, Mark S Anderson, et al.
Pageof 23

Showing results (201-210 of 225) with videos related to

Sort By:
Pageof 23
Diabetes Care|February 2, 2023
CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention StudyDarrell M Wilson, Susan L Pietropaolo, Maria Acevedo-Calado, et al.
Diabetes Care|July 18, 2018
Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA<sub>1c</sub> in New-Onset Type 1 DiabetesMichael J Haller, Desmond A Schatz, Jay S Skyler, et al.
Pancreas|October 7, 2022
Assessing the Pathophysiology of Hyperglycemia in the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis ConsortiumKathleen M Dungan, Phil A Hart, Dana K Andersen, et al.
Diabetes Care|December 12, 2018
Proinsulin Secretion Is a Persistent Feature of Type 1 DiabetesEmily K Sims, Henry T Bahnson, Julius Nyalwidhe, et al.
The New England Journal of Medicine|June 11, 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 DiabetesKevan C Herold, Brian N Bundy, S Alice Long, et al.
Diabetes Care|April 24, 2019
Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care 2019;42:258-264Emily K Sims, Henry T Bahnson, Julius Nyalwidhe, et al.
Pancreas|October 7, 2022
Recruitment and Retention Strategies for the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis ConsortiumCemal Yazici, Anne-Marie Dyer, Darwin L Conwell, et al.
Diabetes|April 11, 2019
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA<sub>1c</sub>, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial DataMichael J Haller, S Alice Long, J Lori Blanchfield, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
Diabetes Care|March 15, 2023
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled TrialWilliam E Russell, Brian N Bundy, Mark S Anderson, et al.
Pageof 23